>
AllerMAbsAllerMAbs
艾乐美生物科技有限公司(AllerMAbs Co., Ltd.)成立于2015年,是台湾一家专注于生产高亲和力、高纯度并具有过敏原特异性的嵌合人类IgE单克隆抗体的生物公司。
AllerMAbs的产品解决了目前人类IgE抗体不易制备的问题,让嵌合人类IgE抗体可以成为人类IgE抗体的替代品,并提供一个更稳定、更符合血清IgE检测系统的校正品,让临床血清IgE的检测结果更加准确与可靠。
其利用动物基因转殖技术,将组成人类IgE抗体分子的ε重链(Heavy chain)和κ轻链(Light chain)的编码基因(Encoding genes),分別嵌入(Knock-in)小鼠胚胎干细胞(Embryonic stem cells, ES cells)的γ1重链和κ轻链基因的位置,接着把胚胎干细胞分別植入孕母鼠体内,并将其带有嵌入基因之成鼠交互配种,最后得到带有人类IgE抗体重链和轻链基因的基因嵌入小鼠(HεκKI mice),且体内能制造完整的嵌合人类IgE抗体分子。
Allermabs is a prevalent disease in both developed and developing countries. IgE plays a major role in allergic diseases despite its low expression in the body. Understanding the relationship between IgE responses and clinical symptoms as well as advancing the IgE detection techniques will significantly improve disease management. However, pure IgE is rare and expensive, which may hamper research and assay development. IgE mAbs, allergen-specific human IgE mAbs in particular, are also very difficult to prepare either by hybridoma or recombinant DNA technologies. These obstacles limit the supply of IgE mAbs on the market. Thus, new technology to produce large quantity and high quality of human IgE mAbs or their equivalents are urgently needed to improve both basic IgE research as well as clinical applications. We have designed a proprietary transgenic mouse in conjunction with hybridoma technologies by which the preparation of IgE hybridomas is more practical and the production of allergen-specific chimeric human IgE is very efficient. These transgenic mice can be immunized to induce the B cell proliferation to overcome the limitation of low numbers of human IgE B cells obtained for making IgE hybridomas. Using allergen-immunized transgenic mice to prepare IgE hybridomas producing allergen-specific chimeric human IgE is also a leading platform in IgE research and production.
Our research team has been studying human IgE and developing antibody production techniques at the Academia Sinica in Taiwan since 2009. We have designed transgenic animals expressing human IgE genes and utilized these animal models to produce IgE mAbs. Recently, we developed a gene knock-in mouse model capable of producing chimeric human IgE antibodies. Using hybridoma technologies, we successfully prepared IgE hybridomas producing allergen-specific chimeric human IgE mAbs and purified the mAbs by affinity chromatography. Our analyses showed that the chimeric human IgE antibodies generated from our system exhibited equivalent biochemical and biological properties to human IgE. To systematically generate large scale of various chimeric human IgE mAbs, we founded AllerMAbs Co., Ltd. and signed an exclusive patent license contract with Academia Sinica. Currently, we are generating chimeric human IgE mAbs specifically reactive towards different allergen components in large scale.
产品列表:
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
50 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
100 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
200 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
500 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
1 mg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
50 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
100 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
200 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
500 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
1 mg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
50 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
100 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
200 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
500 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
1 mg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
50 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
100 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
200 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
500 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
1 mg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
50 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
100 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
200 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
500 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
1 mg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
50 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
100 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
200 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
500 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
1 mg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
100 μg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
500 μg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
1 mg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
5 mg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
10 mg |